iCAD Dividend

Dividend criteria checks 0/6

iCAD no tiene antecedentes de pago de dividendos.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield	1.0%
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Earnings per share	-US$0.27
Dividend yield forecast in 3Y	n/a

Recent dividend updates

No updates

Recent updates

iCAD, Inc. (NASDAQ:ICAD) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Feb 29

Stability and Growth of Payments

Fetching dividends data

Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de ICAD han sido estables en el pasado.

Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de ICAD han aumentado.

Dividend Yield vs Market

iCAD Dividend Yield vs Market

How does ICAD dividend yield compare to the market?
Segment	Dividend Yield
Company (ICAD)	n/a
Market Bottom 25% (US)	1.5%
Market Top 25% (US)	4.7%
Industry Average (Healthcare Services)	1.0%
Analyst forecast in 3 Years (ICAD)	n/a

Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de ICAD en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Alto dividendo: No es posible evaluar la rentabilidad por dividendo de ICAD en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Earnings Payout to Shareholders

Cobertura de los beneficios: No hay datos suficientes para calcular el ratio de reparto de ICAD para determinar si sus dividendos están cubiertos por los beneficios.

Cash Payout to Shareholders

Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que ICAD no ha comunicado ningún pago.

Discover strong dividend paying companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

iCAD Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

Recent updates

iCAD, Inc. Announces Commercial Availability of ProFound Cloud

Consensus revenue estimates fall by 12%

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Share price stability

iCAD, Inc. (NASDAQ:ICAD) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

iCAD, Inc. to Report Q4, 2023 Results on Mar 12, 2024

iCAD, Inc. Appoints Michael John Doyle to its Board of Directors

Forecast to breakeven in 2026

iCAD, Inc. Expands Executive Sales Leadership Team as Business Grows

iCAD, Inc. to Present New Studies Valuating its Artificial Intelligence Powered ProFound Breast Health Suite

iCAD, Inc. to Present New Studies Valuating its Artificial Intelligence Powered ProFound Breast Health Suite

New minor risk - Shareholder dilution

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus revenue estimates decrease by 16%

iCAD, Inc. to Report Q3, 2023 Results on Nov 13, 2023

New minor risk - Profitability

Elekta AB (publ) (OM:EKTA B) agreed to acquire Xoft, Inc. from iCAD, Inc. (NasdaqCM:ICAD).

We're Hopeful That iCAD (NASDAQ:ICAD) Will Use Its Cash Wisely

Consensus EPS estimates upgraded to US$0.37 loss, revenue downgraded

Health Canada Grants Device License for iCAD's Profound Risk 2.0, Revolutionizing Breast Cancer Risk Via A 1-2 Year Assessment

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

iCAD, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Price target increased by 10% to US$4.88

We Think iCAD (NASDAQ:ICAD) Needs To Drive Business Growth Carefully

Consensus EPS estimates fall by 22%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Executive Chair recently bought US$52k worth of stock

No longer forecast to breakeven

Price target decreased by 38% to US$5.08

Will iCAD (NASDAQ:ICAD) Spend Its Cash Wisely?

iCAD, Inc. Appoints Bill Keyes as Senior Vice President, US Commercial Sales, AI

iCAD, Inc. Appoints Dana Brown as Executive Chair of the Board of Directors

iCAD, Inc. Announces Nathaniel Dalton's Resignation from His Position as A Member of the Board

Consensus revenue estimates fall by 11%

Price target decreased to US$8.17

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Is iCAD (NASDAQ:ICAD) In A Good Position To Invest In Growth?

iCAD, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Consensus revenue estimates fall by 15%

Forecast to breakeven in 2024

iCAD, Inc. to Report Q2, 2022 Results on Aug 10, 2022

iCAD, Inc.(NasdaqCM:ICAD) dropped from Russell 2000 Dynamic Index

Companies Like iCAD (NASDAQ:ICAD) Are In A Position To Invest In Growth

iCad, Inc. Announces CFO Changes

Icad, Inc. Announces Chief Financial Officer Changes

Icad, Inc. Announces That New Research Supporting Profound Ai for Digital Breast Tomosynthesis

iCAD, Inc. Announces Promising Clinical Research Supporting Profound Ai(R) Risk for Digital Breast Tomosynthesis

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

iCAD, Inc., Annual General Meeting, Jun 17, 2022

iCAD Announces Significant Commercial Momentum for ProFound AI Among Customers Equipped with the Provider of 3D Mammography Systems

No longer forecast to breakeven

iCAD, Inc. Announces Board Changes

iCAD, Inc. Announces Additional Patients Treated Under GLIOX Trial and Continued Global Momentum for Xoft Intraoperative Radiation Therapy for Brain, Rectal, Head and Neck Tumor Treatment

Consensus EPS estimates fall by 71%

Full year 2021 earnings: EPS exceeds analyst expectations

iCAD (NASDAQ:ICAD) Is In A Good Position To Deliver On Growth Plans

iCAD, Inc. to Report Q4, 2021 Results on Feb 28, 2022

iCAD: Downside Seems Limited

Consensus EPS estimates fall by 11%

iCAD, Inc. (NASDAQ:ICAD) Analysts Just Cut Their EPS Forecasts Substantially

Price target decreased to US$19.43

Forecast breakeven date pushed back to 2024

iCAD, Inc. Provides Revenue Guidance for the Fourth Quarter of 2021 and for the Full Year 2021

iCAD, Inc. announces First Recurrent Glioblastoma Tumor is Treated with Xoft Brain IORT in the United States

Executive Chairman & CEO recently bought US$99k worth of stock

Price target decreased to US$21.43

iCAD, Inc. Announces Compelling New and Real-World Data Demonstrating the Value of ProFound AI to be Presented at RSNA 2021

Chief Technology Officer exercised options and sold US$67k worth of stock

Here's Why We're Not Too Worried About iCAD's (NASDAQ:ICAD) Cash Burn Situation

Third quarter 2021 earnings released: US$0.087 loss per share (vs US$0.078 loss in 3Q 2020)

Price target decreased to US$22.38

High number of new directors

iCAD Unveils Next Generation Technologies at Journées Francophones de Radiologie

iCAD Launches Revolutionary Short-term Personalized Risk Assessment Solution for 3D Mammography